Protocol Ledger

NCT05727904 · Phase III · RECRUITING

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.

Interventional Phase III clinical trial protocol NCT05727904 sponsored by Iovance Biotherapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-03-30 Enrollment: 670 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05727904
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)670 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05727904
Protocol FieldVerified Registry Value
NCT IdentifierNCT05727904
Consolidated Lead SponsorIovance Biotherapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment670 participants (ESTIMATED)
Registered Start Date2023-03-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI